A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Inclusion Criteria: * Body mass index of 18 to 35 kg/m2 * Men and women 18 to 75 years of age, inclusive * Patients need to be non-smokers or ex-smokers (quit ≥ 6 months before the Visit 1) with total smoking history of \< 10 pack years * Documented clinical diagnosis of asthma for ≥ 6 months before the Visit 1 * Patients on low-dose inhaled corticosteroids (ICS) (equivalent of budesonide ≤ 400 μg per day) or low-dose ICS/long-acting β-2 agonist (LABA), or not on any inhaled steroids, or patients on montelukast * Patients should be controlled on low dose budesonide during the first 14 ±2 days of Run-in Part 1, i.e., they need to have ACQ-5 of ≤ 1.5 at Visit 2. * Prebronchodilator FEV1 at Visit 3 should be between 40% and 90% of predicted (mean of 2 predose measurements taken 30 minutes apart). * All patients need to have FeNO concentrations of ≥ 25 parts per billion at Visit 3 * Demonstrate the ability to use the study inhalation device properly * Women must be of nonchildbearing potential defined as meeting 1 of the following criteria: * Permanently or surgically sterilized, including hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy * Postmenopausal; aged ≤ 50 years and have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle stimulating hormone levels in the postmenopausal range * Postmenopausal; aged \> 50 years and have been amenorrheic for 12 months or more,…